0
selected
-
1.
Meta-Analysis of the Effect of Dietary Care on Nausea and Vomiting in Oncology Chemotherapy Patients.
He, J, Xiong, Y, Mo, D, Tang, M
Contrast media & molecular imaging. 2022;2022:3163230
-
-
-
Free full text
Plain language summary
A good diet can provide cancer patients with reasonable and adequate nutrition and strengthen their own immunity, thus enhancing their ability to fight against the adverse effects of cancer treatment. Chemotherapy, as an important treatment for malignant tumours, kills cancer cells and also kills normal cells that are actively proliferating in the body. The aim of this study was to evaluate the efficacy of dietary interventions for the relief of nausea and vomiting after chemotherapy and to provide evidence to support the development of clinical care protocols by summarizing the literature of relevant randomized controlled trials at home and abroad. This study is a systematic review and meta-analysis of 5 studies. Results showed that dietary care reduced the occurrence of nausea and vomiting in chemotherapy patients in general, and the short-term effects were more pronounced. Furthermore, dietary care interventions have a positive effect on the quality-of-life improvement in chemotherapy patients. Dietary care can alleviate the symptoms of nausea and vomiting in tumour chemotherapy patients and improve the quality of life of short-term chemotherapy tumour patients. Authors conclude that effective dietary care can effectively improve the digestive symptoms of chemotherapy cancer patients and reduce and prevent all kinds of digestive reactions, which is worth promoting in cancer clinical care.
Abstract
Objective: To evaluate the effect of dietary care on chemotherapy-induced nausea and vomiting in oncology patients. Methods: A retrospective analysis of digestive symptoms was conducted in cancer patients admitted to our hospital, who received chemotherapy, and corresponding effective dietary care countermeasures were adopted. Results: After the nursing intervention, the incidence of digestive symptoms was significantly reduced, the quality of life was significantly improved (59.92 ± 6.57) vs. (37.95 ± 7.50), and the nursing satisfaction was significantly higher (91.67% vs. 69.44%), with statistically significant differences (P < 0.05). Meta-analysis showed that short-term (0 to 3 months) dietary care could alleviate nausea and vomiting symptoms in chemotherapy patients (P < 0.001) and improve the survival quality of oncology patients (P < 0.01). The effect of long-term (3-6 months) dietary care on the control of nausea and vomiting symptoms in chemotherapy patients was certain (P < 0.05), but the effect on the improvement of their quality of life (P > 0.05) was unclear. Conclusion: Dietary care can alleviate the symptoms of nausea and vomiting in tumor chemotherapy patients and improve the quality of life of short-term chemotherapy tumor patients, so it can be recommended to strengthen the dietary management for tumor patients receiving chemotherapy. Patients receiving chemotherapy should be given corresponding dietary nutritional care according to their clinical symptoms in order to alleviate their adverse reactions, enhance their own immunity, and improve the prognosis of cancer patients.
-
2.
The Functional Medicine Approach To Treating COVID-19 And Post-COVID Syndrome
Dr. Mark Hyman is a practicing family physician and an internationally recognised leader, speaker, educator, and advocate in the field of Functional Medicine. He is the founder and director of The UltraWellness Center, the Head of Strategy and Innovation of the Cleveland Clinic Center for Functional Medicine, a thirteen-time New York Times bestselling author, and Board President for Clinical Affairs for The Institute for Functional Medicine.
2021
Abstract
In this podcast episode, Dr Hyman and his guest, Dr Hanaway, dive into the current state of the Covid-19 pandemic and about their clinical experience treating patients. They emphasise how integrative practices have shown to reduce hospitalizations from Covid 8-times more than conventional treatments alone, pointing out that it’s not about dismissing the conventional treatment methods, but rather bringing together the two. Moreover, they talk about the post-Covid syndrome and how functional and integrative treatments are key in clinical practice when addressing this problem.
-
3.
The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy.
Kim, SH, Lee, SM, Jeung, HC, Lee, IJ, Park, JS, Song, M, Lee, DK, Lee, SM
Nutrients. 2019;11(5)
-
-
-
Free full text
Plain language summary
Despite the advantages of chemotherapy, it can cause cancer-related malnutrition leading to both reduced quality of life and reduced survival rate. Oral nutritional supplements (ONSs) provide balanced nutrients, calories, and protein to complement insufficient oral intake, and ONS provision during treatment may improve nutritional status. The aim of this study was to investigate the impact of ONS on nutritional status in patients undergoing chemotherapy for pancreatic and bile duct cancer. Patients were randomly allocated to the ONS group (15) and non-ONS group (19) and dietary intake and body weight were assessed at weeks 1, 2, 4 and 8. Body composition and quality of life was assessed at baseline and week 8. This study found the supply of ONS helped promote health by increasing body fat mass, improving quality of life and decreasing fatigue symptoms in pancreatic and bile duct cancer patients. These results were more pronounced in patients in the first cycle of chemotherapy. Based on these results, the authors conclude ONS may improve nutritional status by increasing fat mass and/or maintaining the body composition of patients undergoing chemotherapy.
Abstract
Chemotherapy may negatively affect nutritional status and quality of life (QOL) in pancreatic cancer patients. Our aim was to investigate the beneficial effects of oral nutrition supplements (ONS) on pancreatic and bile duct cancer patients undergoing chemotherapy. Among patients with progressive pancreatic and bile duct cancer receiving chemotherapy, the ONS group (n = 15) received two packs of ONS daily for 8 weeks while the non-ONS group (n = 19) did not. Anthropometric measures, dietary intake, nutritional status, and quality of life were assessed. ONS significantly increased daily intakes of energy, carbohydrates, proteins, and lipids at 8 weeks compared to the baseline. After 8 weeks, fat mass significantly increased in the ONS group. For patients in their first cycle of chemotherapy, body weight, fat-free mass, skeletal muscle mass, body cell mass, and fat mass increased in the ONS group but decreased in the non-ONS group. Fat mass increased in second or higher cycle only in the ONS group. Patient-generated subjective global assessments (PG-SGA) and fatigue scores in the Quality of Life Questionnaire Core 30 (QLQ-C30) improved in the ONS group. ONS might improve nutritional status by increasing fat mass and/or maintaining the body composition of pancreatic and bile duct cancer patients with chemotherapy, especially those in the first cycle, and alleviate fatigue symptoms.
-
4.
Moderate Physical Activity Mediates the Association between White Matter Lesion Volume and Memory Recall in Breast Cancer Survivors.
Cooke, GE, Wetter, NC, Banducci, SE, Mackenzie, MJ, Zuniga, KE, Awick, EA, Roberts, SA, Sutton, BP, McAuley, E, Kramer, AF
PloS one. 2016;11(2):e0149552
-
-
-
Free full text
Plain language summary
As survival rates of breast cancer increase, the long-term cognitive effects of disease and required treatment are emerging. The underlying pathways of cancer-related cognitive impairment involve accelerated aging of the brain, low levels of physical activity and decreased cognitive function, however these links have not been adequately explored. The aim of this study was to investigate the link between physical activity, white matter lesion volume and cognition in 30 breast cancer survivors and 28 age-matched controls. The results of this study showed that brain structure significantly predicted cognitive function. This study provided evidence suggesting that moderate physical activity may help reduce the treatment related risks associated with breast cancer.
Abstract
Increased survival rates among breast cancer patients have drawn significant attention to consequences of both the presence of cancer, and the subsequent treatment-related impact on the brain. The incidence of breast cancer and the effects of treatment often result in alterations in the microstructure of white matter and impaired cognitive functioning. However, physical activity is proving to be a successful modifiable lifestyle factor in many studies that could prove beneficial to breast cancer survivors. This study investigates the link between white matter lesion volume, moderate physical activity, and cognition in breast cancer survivors following treatment compared to non-cancer age-matched controls. Results revealed that brain structure significantly predicted cognitive function via mediation of physical activity in breast cancer survivors. Overall, the study provided preliminary evidence suggesting moderate physical activity may help reduce the treatment related risks associated with breast cancer, including changes to WM integrity and cognitive impairment.
-
5.
Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study.
Bacić, I, Druzijanić, N, Karlo, R, Skifić, I, Jagić, S
Journal of experimental & clinical cancer research : CR. 2010;29:12
-
-
-
Free full text
Plain language summary
Breast cancer is the most common cancer in women worldwide. Treatment options include surgery, chemotherapy, ionising radiation, hormone therapy and supportive measures that aim to reduce the side effects of treatment. Inositol hexaphosphate (IP6) is a naturally occurring compound which is important in regulating vital cellular functions and has been shown to have anticancer properties. The aim of this randomised, controlled pilot study was to evaluate if the combination of IP6+Inositol alongside traditional chemotherapy will increase efficacy and decrease side effects of chemotherapy, and improve the quality of life. 14 breast cancer patients were randomised to receive either IP6+inositol or vitamin C (control, amount not reported) for 6 months during chemotherapy. Patients receiving IP6+inositol had significantly better quality of life and functional status and significantly less side effects than the control group. Unlike the control group, patients on IP6+inositol had no drop in white blood cells and platelets (common side effects of chemotherapy). There was no difference in other blood tests and tumour markers between the groups. The authors conclude that IP6+ Inositol, used as an adjunctive therapy, may help ameliorating side effects of chemotherapy and preserve quality of life in breast cancer patients.
Abstract
BACKGROUND Prospective, randomized, pilot clinical study was conducted to evaluate the beneficial effects of inositol hexaphosphate (IP6) + Inositol in breast cancer patients treated with adjuvant therapy. PATIENTS AND METHODS Patients with invasive ductal breast cancer where polychemotherapy was indicated were monitored in the period from 2005-2007. Fourteen patients in the same stage of ductal invasive breast cancer were involved in the study, divided in two randomized groups. One group was subjected to take IP6 + Inositol while the other group was taking placebo. In both groups of patients the same laboratory parameters were monitored. When the treatment was finished, all patients have filled questionnaires QLQ C30 and QLQ-BR23 to determine the quality of life. RESULTS Patients receiving chemotherapy, along with IP6 + Inositol did not have cytopenia, drop in leukocyte and platelet counts. Red blood cell counts and tumor markers were unaltered in both groups. However, patients who took IP6 + Inositol had significantly better quality of life (p = 0.05) and functional status (p = 0.0003) and were able to perform their daily activities. CONCLUSION IP6 + Inositol as an adjunctive therapy is valuable help in ameliorating the side effects and preserving quality of life among the patients treated with chemotherapy.